非酒精性脂肪性肝病中医诊疗专家共识(2023)

中华中医药学会脾胃病分会. 非酒精性脂肪性肝病中医诊疗专家共识(2023)[J]. 中国中西医结合消化杂志, 2024, 32(1): 1-7. doi: 10.3969/j.issn.1671-038X.2024.01.01
引用本文: 中华中医药学会脾胃病分会. 非酒精性脂肪性肝病中医诊疗专家共识(2023)[J]. 中国中西医结合消化杂志, 2024, 32(1): 1-7. doi: 10.3969/j.issn.1671-038X.2024.01.01
Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on Traditional Chinese Medicine diagnosis and treatment of non-alcoholic fatty liver disease(2023)[J]. Chin J Integr Tradit West Med Dig, 2024, 32(1): 1-7. doi: 10.3969/j.issn.1671-038X.2024.01.01
Citation: Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on Traditional Chinese Medicine diagnosis and treatment of non-alcoholic fatty liver disease(2023)[J]. Chin J Integr Tradit West Med Dig, 2024, 32(1): 1-7. doi: 10.3969/j.issn.1671-038X.2024.01.01

非酒精性脂肪性肝病中医诊疗专家共识(2023)

  • 基金项目:
    上海市进一步加快中医药传承创新发展三年行动计划:中医药临床研究高地建设-中医药优势病种循证医学技术支撑平台建设[No:ZY(2021-2023)-0211]
详细信息

Expert consensus on Traditional Chinese Medicine diagnosis and treatment of non-alcoholic fatty liver disease(2023)

  • 非酒精性脂肪性肝病是临床最常见的慢性肝病之一,中华中医药学会脾胃病分会于2009、2017年发布了《非酒精性脂肪性肝病中医诊疗共识意见》。近年来,中医药在非酒精性脂肪性肝病辨证治疗、证候规律研究等方面取得了积极进展,有必要对中医诊疗共识意见进行更新。本共识内容涵盖非酒精性脂肪性肝病的中西医诊断、病因病机、辨证论治方法、预防转归等,且总结了本病的现代医家经验、循证医学进展及疗效评价标准。本共识突出临床实用性,体现了最新研究进展,以期进一步提高中医药防治非酒精性脂肪性肝病的临床及科研水平。
  • 加载中
  • 图 1  NAFLD的中医诊疗流程图

  • [1]

    Wu YK, Zheng Q, Zou BY, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis[J]. Hepatol Int, 2020, 14(2): 259-269. doi: 10.1007/s12072-020-10023-3

    [2]

    张声生, 李军祥. 非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J]. 中医杂志, 2017, 58(19): 1706-1710.

    [3]

    国家中医药管理局, 国家卫生健康委员会. 国家中医药管理局、国家卫生健康委员会关于印发《中医病证分类与代码》和《中医临床诊疗术语》的通知[EB/OL]. (2020-11-16)[2023-02-01]. https://www.gov.cn/zhengce/zhengceku/2020-11/24/content_55603.htm.

    [4]

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 中华肝脏病杂志, 2018, 26(3): 195-203. doi: 10.3760/cma.j.issn.1007-3418.2018.03.008

    [5]

    European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1): 237-264. doi: 10.1016/j.jhep.2015.04.006

    [6]

    Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis[J]. J Hepatol, 2017, 66(5): 1022-1030. doi: 10.1016/j.jhep.2016.12.022

    [7]

    Zhang YN, Fowler KJ, Hamilton G, et al. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging[J]. Br J Radiol, 2018: 20170959. doi: 10.1259/bjr.20170959

    [8]

    Rinella ME, Tacke F, Sanyal AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD[J]. J Hepatol, 2019, 71(4): 823-833. doi: 10.1016/j.jhep.2019.04.019

    [9]

    Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review[J]. JAMA, 2020, 323(12): 1175-1183. doi: 10.1001/jama.2020.2298

    [10]

    Nascimbeni F, Ballestri S, Machado MV, et al. Clinical relevance of liver histopathology and different histological classifications of NASH in adults[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(4): 351-367. doi: 10.1080/17474124.2018.1415756

    [11]

    Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. doi: 10.1016/j.jhep.2020.03.039

    [12]

    Ahadi M, Molooghi K, Masoudifar N, et al. A review of non-alcoholic fatty liver disease in non-obese and lean individuals[J]. J Gastroenterol Hepatol, 2021, 36(6): 1497-1507. doi: 10.1111/jgh.15353

    [13]

    李敏谦, 林育, 项磊, 等. 基于临床文献的非酒精性脂肪性肝病证候分布规律研究[J]. 世界中医药, 2019, 14(1): 6-11. doi: 10.3969/j.issn.1673-7202.2019.01.002

    [14]

    赵文霞, 张丽慧, 刘晓彦. 张磊运用涤浊法论治非酒精性脂肪性肝病经验[J]. 中医杂志, 2019, 60(23): 1993-1996.

    [15]

    吴大真, 李瑶, 杨建宇. 国医大师验案良方-肝胆肾卷[M]. 北京: 学苑出版社, 2010: 104-105.

    [16]

    李合国. 国医大师李振华教授从脾论治非酒精性脂肪肝经验[J]. 中医研究, 2011, 24(7): 62-63. doi: 10.3969/j.issn.1001-6910.2011.07.033

    [17]

    蔡媛媛, 程亚伟, 蔡敏, 等. 罗凌介辨治脂肪肝的经验总结[J]. 中医药导报, 2018, 24(20): 129-131.

    [18]

    Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4): 829-846. doi: 10.1016/j.jhep.2017.05.016

    [19]

    Dai L, Ooi VV, Zhou WJ, et al. Acupoint embedding therapy improves nonalcoholic fatty liver disease with abnormal transaminase: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine(Baltimore), 2020, 99(3): e18775.

    [20]

    Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2013, 38(2): 134-143. doi: 10.1111/apt.12352

    [21]

    Pan JL, Wang M, Song HY, et al. The efficacy and safety of traditional Chinese medicine(Jiang Zhi Granule)for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study[J]. Evid Based Complement Alternat Med, 2013, 2013: 965723.

    [22]

    李军祥, 王允亮, 刘敏, 等. 健脾疏肝方治疗非酒精性脂肪性肝炎多中心、随机、对照的临床研究[J]. 中国中西医结合杂志, 2014, 34(1): 15-19.

    [23]

    郁强, 张声生, 周滔, 等. 调肝理脾方治疗非酒精性脂肪性肝病肝郁脾虚证的随机对照研究[J]. 中国中西医结合杂志, 2015, 35(4): 401-405.

    [24]

    唐海鸿, 魏春山, 郑颖俊, 等. 基于FibroScan技术评价疏肝消脂方加减治疗非酒精性脂肪性肝病的临床疗效[J]. 中医杂志, 2018, 59(7): 594-598.

    [25]

    唐金模, 梁惠卿, 王宏国, 等. 皂术茵陈方治疗非酒精性脂肪性肝炎的临床疗效及对游离脂肪酸和TNF-α的影响[J]. 中国中西医结合杂志, 2016, 36(5): 544-548.

    [26]

    Dai L, Xu JJ, Liu BC, et al. Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach[J]. Front Med, 2022, 16(5): 745-759.

    [27]

    绽永华, 王学红, 王芳. 半夏泻心汤加减对非酒精性脂肪肝的临床疗效及对胰岛素抵抗的调节效果观察[J]. 中国实验方剂学杂志, 2021, 27(3): 117-122.

    [28]

    Liang ZJ, Chen XW, Shi JN, et al. Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials[J]. Chin Med, 2021, 16(1): 1-38.

    [29]

    Dai L, Zhou WJ, Zhong LLD, et al. Chinese medicine formulas for nonalcoholic fatty liver disease: overview of systematic reviews[J]. World J Clin Cases, 2021, 9(1): 102-117.

  • 加载中

(1)

计量
  • 文章访问数:  6588
  • PDF下载数:  5358
  • 施引文献:  0
出版历程
收稿日期:  2023-11-20
刊出日期:  2024-01-15

目录